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Graft-versus-Host Disease (GvHD) is the most serious complication of allogeneic stem cell transplantation (SCT) and results
from an activation of donor lymphocytes by recipient antigen-presenting cells (APCs). For a long time, it has been postulated
that the intestinal microﬂora and endotoxin exert a crucial step in this APC activation, as there is early and severe gastrointestinal
damage induced by pretransplant conditioning. With the detailed description of pathogen-associated molecular patterns and
pathogen recognition receptors single nucleotide polymorphisms of TLRs and especially NOD2 have been identiﬁed as potential
risk factors of GvHD and transplant related complications thus further supporting the crucial role of innate immunity in SCT,
related complications. Gastrointestinal decontamination and neutralization of endotoxin have been used to interfere with this
early axis of activation with some success but more speciﬁc approaches of modulation of innate immunity are needed for further
improvement of clinical outcome.
1.Introduction
Graft-versus-Host Disease (GvHD) in its acute and chronic
formisthemajorcauseofmortalityandmorbidityfollowing
both, experimental and clinical allogeneic stem cell trans-
plantation (SCT). Donor T-cells activated by major or minor
histocompatibility antigens on host antigen presenting cells
(APCs) are the essential players in the pathophysiology
of GvHD [1], and T-cell depletion of the graft is able
to abrogate both, GvHD and the beneﬁcial graft-versus-
leukemia(GvL)eﬀect.However,ithasbeenwellknownsince
the fundamental experiments of van Bekkum that activation
of innate immunity by the gastrointestinal microﬂora is
a crucial and initiating step in induction of alloreactions.
Mice grown under germ-free conditions and receiving bone
marrow as the only stem cell source (containing a limited
number of T-cells) failed to develop acute GvHD whereas,
mice grown under conventional conditions or reconvention-
alized early after transplantation died from acute GvHD.
If spleen cells containing a high number of T-cells were
added, germ-free conditions could not prevent but still
delayed the onset of GvHD [2]. Since this ﬁrst observation
substantial progress has been made in understanding the
exact pathways how bacteria and their ligands interact with
speciﬁcpatternrecognitionreceptors(PRRs),thusactivating
and modulating APCs and targets of GvHD. In the present
paper we summarize current evidence on the impact of
microbia and microbial patterns on pathophysiology of
GvHD and clinical outcome following allogeneic SCT.
2. IndirectEvidence:Gastrointestinal
Damage andGvHD
Major target organs of acute GvHD are the skin, the liver,
especially bile duct epithelia, the gastrointestinal tract and
still controversially discussed, the lung. In chronic GvHD,
oral manifestations and again, the pulmonary involvement
of bronchiolitis obliterans (BOs) are frequent. A common
denominator of these organs is that they present epithelial
surfaces with strong immunological interactions between
commensal and pathogenic bacteria, epithelial barrier and
defence mechanisms and the immune system which are
usually in a perfect balance to maintain a status of immuno-
logical tolerance [3].
These epithelial defence mechanisms are heavily
disturbed by epithelial damage through pretransplant2 International Journal of Inﬂammation
conditioning which is the ﬁrst step in the SCT procedure
and includes high-dose cytotoxic therapy or total body
irradiation (TBI). Although conditioning aims to eliminate
the recipient’s leukemia and achieve myeloablation, in
both, experimental and clinical SCT, it has become clear
that increasing the dose of TBI from 900 to 1300cGy in
mice and from 12 to 15,5Gy clinically was associated with
increased epithelial damage, more severe GvHD and inferior
outcome [4–6]. Similarly, an increased area under the curve
(AUC) following exposure to intravenous busulfan was also
associated with increased gastrointestinal toxicity and acute
GvHD [7].
In 2 clinical trials, gastrointestinal toxicity was directly
assessed by either monitoring diarrhea during the aplastic
phase [8] or direct analysis of intestinal permeability [9]a n d
could be correlated with severity of subsequent acute GvHD.
In line with this, prophylactic treatment of mice with the rhu
Keratinocyte Growth Factor (KGF) protected from apoptosis
of intestinal epithelial cells, LPS mediated TNF release, and
ﬁnally lethal GvHD [10] while maintaining GvL eﬀects [11].
However, in a randomized clinical trial KGF reduced severity
of mucositis in patients receiving TBI but did not aﬀect
GvHD and outcome as expected from murine data [12].
3. IndirectEvidence: The Role of
SNPs of InnateImmunity
In murine GvHD, endotoxin has been identiﬁed as a major
mediator of inﬂammation involved in initiation of intestinal
and systemic GvHD. Genetic susceptibility as well as direct
antagonisms against endotoxin has a major impact on the
occurrence and severity of experimental GvHD [5, 13]a n d
anLPS-TNFαaxishasbeenpostulatedasamajormechanism
o fa c u t eG v H D .I nh u m a n s ,T L R 4i sc o n s i d e r e dt or e p r e s e n t
the classical endotoxin receptor. With the characterization
of the human genome, single nucleotide polymorphisms
(SNPs) for many genes have been described which translate
into altered functions of these genes. In the setting of
allogeneic SCT, TLR4 SNPs have been assessed by 2 groups
which however, reported opposing eﬀects, either protection
or enhancement of GvHD in the presence of TLR4 SNPs
[14, 15].
Beyond TLR4, there is a large set of further TLRs rec-
ognizing other microbial patterns including further bacterial
and viral ligands. SNPs have been described for most of
these TLRs, and recently, presence of the homozygous TLR9
variant in the patient has been associated with improved
survival and a reduced relapse rate following allogeneic
SCT [16]. In addition to TLRs, the NOD-like receptors are
a family of highly conserved intracytoplasmatic receptors
involvedinactivationofanimportantinﬂammatorycascade,
the inﬂammasome, which ﬁnally results in activation of
NF-κB and/or activation and cleavage of IL-1β [17]. Based
on pathophysiological similarities between inﬂammatory
bowel disease and intestinal GvHD, we speculated that SNPs
involved in the pathogenesis of Crohn’s disease might be also
ofrelevanceinGvHDandoutcomefollowingallogeneicSCT
[18]. We and others have therefore tested SNPs of NOD2,
a receptor sensing muramyl-dipeptide derived from Gram-
p o s i t i v ea n dG ra m - n e g a t i v eb a c t e ri a ,a sw e l la sS N P so fo t h e r
innate immunity molecules such as the autophagy-related
gene 1 (ATG16L1) involved in autophagy of bacteria [18],
in large cohorts of patients receiving HLA-identical sibling
SCT and their donors. Presence of any NOD2 SNPs or
the ATG16L1 variants in either the recipient or the donor
increasedtheriskofGvHDandsubsequenttreatmentrelated
mortality, and this eﬀect was further increased if variants
were present in both, donor and recipient (Figure 1).
Since our ﬁrst description of association of NOD2
variants with GvHD and mortality [19] several further
groups addressed the role of this important receptor. In
HLA-identical sibling transplants, most of the studies were
conﬁrmatory [20–24]; in unrelated donor transplantation,
the association either was absent [25], present only for
SNP13 [26] or even contradictory as one group reported
associationwithlessGvLandmorerelapse[27–29](T able1).
This may be explained by the fact that in unrelated donor
SCT HLA-diﬀerences are much more likely to occur and
dominant against the SNPs of innate immunity or by the
more intense immunosuppression which usually includes in
vivo T-cell depletion with monoclonal or polyclonal sera. In
addition, our European cohort analysis nicely demonstrated
that diﬀerences in transplant speciﬁc strategies, especially
with regard to antibacterial decontamination, had a strong
impact on the prognostic signiﬁcance of NOD2. Thus,
immunoregulatory SNPs may be speciﬁcally sensitive to
interaction with transplant or center-speciﬁc strategies and
it may be therefore diﬃcult to establish these SNPs as risk
factors allowing exact prediction of complications.
However, a further and even more important aspect
of these observations is the implication of these molecules
in pathophysiology. Our observation of an association of
bronchiolitis obliterans syndrome with NOD2 SNPs sug-
gest that this interference of SNPs with epithelial defence
mechanisms applies to all epithelial tissues [30], and it
will be of major interest to learn more about antibacterial
peptides released like defensins released under the control
of NOD2 [31]. Recently, NOD2−/− mice and bone marrow
chimeras were used as recipients in experimental BMT
models. These data conﬁrmed an accelerated mortality from
GvHD if hematopoietic cells were NOD2 deﬁcient, and
O’ Penack and his group identiﬁed the antigen-presenting
cell (APC) as the target of NOD2 deﬁciency [32]. APCs
from NOD2−/− mice induced a much stronger alloreaction
as compared to wild-type mice pointing to a deﬁciency
of immunoregulatory APC molecules. Recently, our group
addressed the immunohistopathology of skin and gut GvHD
in relation to absence and presence of NOD2 SNPs: In
both tissues, skin and gut, recipient NOD2 SNPs had no
impact on the extent of apoptosis as the hallmark of GvHD
nor on the CD8 and macrophage inﬁltrate in the biopsies.
However, we observed a uniform reduction of CD4 cells
in the presence of NOD2 SNPs suggesting that GvHD
especially in these patients is characterized by a loss of
protective CD4 population including a loss of regulatory T-
cells [33]. NOD2 has been shown to be involved in release of
chemokinesattractingT-helpercellsaswellasinrecruitmentInternational Journal of Inﬂammation 3
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Figure 1: Treatment-related mortality and SNPs of innate immu-
nity. SNPs 8,12 and 13 of NOD2 (n = 358) and the T300A. SNP
of ATG16L1 (n = 127) were assessed by PCR in patients receiving
allogeneic SCT and their respective HLA-identical sibling donors.
Cumulative treatment related mortality as calculated by Kaplan-
MeiermethodisshowninrelationtoabsenceofanySNPs(wt,wild-
type) or presence of SNPs (variant, var) in recipients (R) and/or
donors (D). Both associations were signiﬁcant by log rank tests
(P = .003 for NOD2, P = .03 for ATG16L1).
of TH17 cells, and ongoing studies try to address these
questions. Thus, a dysregulated APC function is the most
likely explanation for this loss of CD4 cells as it has been
observed in mice.
4. DirectEvidence: The Role of
BacteriaandBacterialLigands
van Bekkum’s work elegantly elaborated the role of the
intestinal microﬂora and is up to now the basis for the
gnotobiotic approach to modulate GvHD. In his early
experiments he did not only show protection from GvHD
induced by bone marrow transplantation in gnotobiotic
mice. He also reported that subcutaneous fetal gut implants
revealed attenuated histopathological GvHD if the carrier
mice were germ-free prior to allogeneic transplantation
indicating a systemic eﬀect of decontamination [34]. Similar
observations pointing to a systemic modulation [35]w e r e
reported by Lampert et al. [35], as they reported attenuation
of both gut and skin GvHD after oral decontamination in
mice. In the same year, Veenendaal et al. published strain-
dependent eﬀects of decontamination, as C3H/He recipients
wereprotectedfromdelayedtypeGvHDbydecontamination
whereas C57Bl/6 were not [36]. Later on, a debate started
whether selective decontamination versus decontamination
including anaerobic bacteria conferred greater protection
from GvHD. In both, experimental BMT [37] and in clinical
trials published by the Essen group [38, 39] suppression of
the anearobic ﬂora seemed to have a stronger eﬀect than
suppression of enterobacteriaceae alone.
Further evidence for a role of the intestinal ﬂora can
be derived from attempts to neutralize endotoxin. In 1987,
Cohen reported protection of mice by passive immunization
with anti-E.coli sera, and an increased antibody titer against
ac e r t a i nE. coli strain in patients was associated with a
lower incidence of severe GvHD [40, 41]. In the 90s, IgM
enriched immunoglobulin preparations were thought to
reduce GvHD due to their potent antiendotoxin eﬀects [42].
Based on positive reports in inﬂammatory bowel disease,
our group tested the use of probiotic bacteria (Lactobacillus
rhamnosus) in an experimental BMT model. Indeed, feeding
of lactobacilli reduced severity of experimental GvHD and
improved survival. The systemic eﬀect of probiotic bacteria
couldbedemonstratedbyareductionofsplenicdonorT-cell
proliferation further demonstrating that activation of innate
immunity sets the state for subsequent adaptive alloreactions
[43].
Besides endotoxin modulation, only rare reports have
addressed the role of other bacterial and TLR ligands. In
an elegant study, Chakraverty et al. proved the checkpoint
function for innate immunity by applying a TLR7 activator
locally to the skin before inducing GvHD by donor lympho-
cyte infusion in mixed murine chimeras. Whereas there were
almost no cellular inﬁltrates and signs of GvHD in untreated
control skin, massive T-cell inﬁltrates and histopathological
damage was observed in the TLR7ligand pretreated skin
[44]. Similar processes of activation should occur in the
intestinal tract and in other epithelial target tissues of GvHD
after TLR4 and TLR2 binding of endotoxins. In line with
the checkpoint function of innate immunity, binding of
CPG-oligodeoxynucleotides to host antigen-presenting cells
accelerated GvHD in a recent murine study [45], whereas
murine TLR9−/− recipients were protected from GvHD [46].
Interestingly, other TLR-ligands seem to induce opposing
and even silencing eﬀects. Pretreatment of mice with the
TLR5 ligand ﬂagellin reduced severity of GvHD indicating
that TLR5 may be more involved in dampening activation of
antigen presenting cells (Gerwitz, ASBMT 2010, abstract).
5. Perspective: Modulation of PRRs to
Avoid GvHDWhile PreservingGvLEffects
Since many years, attempts to reduce GvHD frequently also
aﬀected the major therapeutic principle of allogeneic SCT,
the graft-versus-leukemia eﬀect. This was most obvious for
direct T-cell depletion [47] but can also be observed for
classical immunosuppressants like cyclosporin. Especially in
acute leukemias, occurrence of mild acute GvHD grade I-II
and chronic GvHD confers the best antileukemic eﬀect. In
our studies on theroleofNOD2 SNPs,however,we observed
a strong impact of recipient and combined donor/recipient
SNPsonGvHD,andGvHD-relatedmortality,however,there
was no diﬀerence in relapse rates between the diﬀerent4 International Journal of Inﬂammation
Table 1: Summary of published studies on NOD2 SNPs and outcome following SCT.
Type of SCT Association Comment Refereces
Holler 2004 Related GvHD, TRM Single centre [17]
Holler 2006 Related GvHD, TRM, OS Multicentre; Impact of
decontamination [18]
Granell 2006 Related TRM, pulmonary compl. CD34 selected grafts [19]
Sairaﬁ 2008 Related No association Low frequency of NOD2 variants [22]
Hanssen 2008 Related Weak with GvHD [20]
Van Velden 2009 Related Strong with GvHD Partially T depleted Grafts [21]
Hildebrandt 2009 Related and Unrelated Bronchiolitis obliterans [28]
Mayor 2009 Unrelated Strong with relapse, not with GvHD Majority received T-cell depletion
With MabCampath [25]
Holler 2009 Unrelated Only SNP13 with TRM [24]
Ngyen 2010 Unrelated No [23]
groups. Patients with wild-type NOD2 had a cumulative
incidence of relapse of 41%, patients with either recipient
or donor variants of 29% and patients with combined
donor and recipient variants 33% [20]. This observation and
pathophysiological considerations suggest that modulation
of epithelial inﬂammation in the gut or the bronchial
epithelial system thus might reduce GvHD but should not
interfere with antileukemic immunity which is located in the
central lymph nodes or in the marrow.
6. Conclusions
Although our current understanding of the interplay
between intestinal microbes, activation of innate immunity,
and speciﬁc alloreactions explains some of the long standing
preclinical and clinical ﬁndings such as the potential pro-
tective eﬀect of intestinal decontamination, there are still a
variety of issues to be solved. Comparable to the situation
in IBD, SNPs of innate immunity alone by far do not
explain the individual susceptibility for intestinal GvHD or
allow even prediction of intestinal GvHD which would be
extremely helpful to tailor immunosuppressive prophylaxis
and treatment suggesting that intestinal homeostasis is far
more complex. In addition, the role of the diversity of
the intestinal microbiota and the impact of immunological
memory against these antigens in GvHD has not been
addressed so far. In addition, pathophysiology has focussed
on excess inﬂammation so far. As suggested by our ﬁndings
on a reduction of intestinal regulatory T-cells in patients
with NOD2 SNPs and GvHD, GvHD may be far more
a loss of intestinal immunoregulation, and mechanisms
of immunoregulation need to be investigated in detail.
Recent data indicate that the balance of regulatory to TH17
cells is strongly regulated by the enzyme Indolamine-2,3
dioxygenase (IDO) in intestinal antigen-presenting cells.
Experimental data suggest a strong impact of this enzyme
in GvHD pathophysiology [48], and ongoing studies address
this new player in the clinical setting. In the long term, these
ﬁndings should help to substitute nonspeciﬁc immuno-
suppression for treatment of intestinal GvHD by strategies
aiming at reconstitution of immunoregulation.
References
[ 1 ]J .L .F e r r a r a ,J .E .L e v i n e ,P .R e d d y ,a n dE .H o l l e r ,“ G r a f t -
versus-hostdisease,”Lancet,vol.373,no.9674,pp.1550–1561,
2009.
[ 2 ]D .W .v a nB e k k u m ,J .R o o d e n b u r g ,P .J .H e i d t ,a n dD .v a n
der Waaij, “Mitigation of secondary disease of allogeneic
mouse radiation chimeras by modiﬁcation of the intestinal
microﬂora,” Journal of the National Cancer Institute, vol. 52,
no. 2, pp. 401–404, 1974.
[3] J .M.W ells,L.M.P .Loonen,andJ .M.K ar czewski,“Ther oleof
innatesignalinginthehomeostasisoftoleranceandimmunity
in the intestine,” International Journal of Medical Microbiology,
vol. 300, pp. 41–48, 2010.
[4] G. R. Hill and J. L. M. Ferrara, “The primacy of the
gastrointestinal tract as a target organ of acute graft-versus-
host disease: rationale for the use of cytokine shields in
allogeneic bone marrow transplantation,” Blood, vol. 95, no.
9, pp. 2754–2759, 2000.
[ 5 ]K .R .C o o k e ,A .G e r b i t z ,J .M .C r a w f o r de ta l . ,“ L P Sa n t a g -
onism reduces graft-versus-host disease and preserves graft-
versus-leukemia activity after experimental bone marrow
transplantation,” Journal of Clinical Investigation, vol. 107, no.
12, pp. 1581–1589, 2001.
[6] R. A. Clift, C. D. Buckner, F. R. Appelbaum et al., “Allo-
geneic marrow transplantation in patients with acute myeloid
leukemia in ﬁrst remission: a randomized trial of two irradia-
tion regimens,” Blood, vol. 76, no. 9, pp. 1867–1871, 1990.
[7] B. S. Andersson, P. F. Thall, T. Madden et al., “Busulfan
systemic exposure relative to regimen-related toxicity and
acute graft-versus-host disease: deﬁning a therapeutic window
for IV BuCy2 in chronic myelogenous leukemia,” Biology of
Blood and Marrow Transplantation, vol. 8, no. 9, pp. 477–485,
2002.
[ 8 ]J .G o l d b e r g ,D .A .J a c o b s o h n ,M .L .Z a h u r a k ,a n dG .B .
Vogelsang, “Gastrointestinal toxicity from the preparative
regimen is associated with an increased risk of graft-versus-
host disease,” Biology of Blood and Marrow Transplantation,
vol. 11, no. 2, pp. 101–107, 2005.
[9] J.-E. Johansson and T. Ekman, “Gut toxicity during hemopoi-
etic stem cell transplantation may predict acute graft-versus-
host disease severity in patients,” Digestive Diseases and
Sciences, vol. 52, no. 9, pp. 2340–2345, 2007.
[10] C. A. Ellison, S. A. Natuik, J. M. M. Fischer et al., “Eﬀect of
recombinant human keratinocyte growth factor (rHuKGF) onInternational Journal of Inﬂammation 5
the immunopathogenesis of intestinal graft-vs.-host disease
induced without a preconditioning regimen,” Journal of
Clinical Immunology, vol. 24, no. 2, pp. 197–211, 2004.
[11] O. I. Krijanovski, G. R. Hill, K. R. Cooke et al., “Keratinocyte
growth factor separates graft-versus-leukemia eﬀects from
graft-versus-host disease,” Blood, vol. 94, no. 2, pp. 825–831,
1999.
[12] B. R. Blazar, D. J. Weisdorf, T. DeFor et al., “Phase 1/2 ran-
domized, placebo-control trial of palifermin to prevent graft-
versus-host disease (GVHD) after allogeneic hematopoietic
stem cell transplantation (HSCT),” Blood, vol. 108, no. 9, pp.
3216–3222, 2006.
[13] K. R. Cooke, K. Olkiewicz, N. Erickson, and J. L. M. Ferrara,
“Theroleofendotoxinandtheinnateimmuneresponseinthe
pathophysiology of acute graft versus host disease,” Journal of
Endotoxin Research, vol. 8, no. 6, pp. 440–448, 2002.
[14] A. H. Elmaagacli, M. Koldehoﬀ, H. Hindahl et al., “Mutations
in innate immune system NOD2/CARD 15 and TLR-4
(Thr399Ile) genes inﬂuence the risk for severe acute graft-
versus-host disease in patients who underwent an allogeneic
transplantation,” Transplantation, vol. 81, no. 2, pp. 247–254,
2006.
[15] E. Lorenz, D. A. Schwartz, P. J. Martin et al., “Association of
TLR4 mutations and the risk for acute GVHD after HLA-
matched-sibling hematopoietic stem cell transplantation,”
Biology of Blood and Marrow Transplantation,v o l .7 ,n o .7 ,p p .
384–387, 2001.
[16] A. H. Elmaagacli, M. Koldehoﬀ, and D. W. Beelen, “Improved
outcome of hematopoietic SCT in patients with homozygous
gene variant of Toll-like receptor 9,” Bone Marrow Transplan-
tation, vol. 44, no. 5, pp. 295–302, 2009.
[17] F. Martinon, A. Mayor, and J. Tschopp, “The inﬂammasomes:
guardians of the body,” Annual Review of Immunology, vol. 27,
pp. 229–265, 2009.
[18] J. Hampe, A. Franke, P. Rosenstiel et al., “A genome-
wide association scan of nonsynonymous SNPs identiﬁes a
susceptibility variant for Crohn disease in ATG16L1,” Nature
Genetics, vol. 39, no. 2, pp. 207–211, 2007.
[19] E. Holler, G. Rogler, H. Herfarth et al., “Both donor and recip-
ient NOD2/CARD15 mutations associate with transplant-
related mortality and GvHD following allogeneic stem cell
transplantation,” Blood, vol. 104, no. 3, pp. 889–894, 2004.
[20] E. Holler, G. Rogler, J. Brenmoehl et al., “Prognostic signif-
icance of NOD2/CARD15 variants in HLA-identical sibling
hematopoietic stem cell transplantation: eﬀect on long-term
outcome is conﬁrmed in 2 independent cohorts and may be
modulated by the type of gastrointestinal decontamination,”
Blood, vol. 107, no. 10, pp. 4189–4193, 2006.
[21] M. Granell, A. Urbano-Ispizua, J. I. Ar´ ostegui et al., “Eﬀect
of NOD2/CARD15 variants in T-cell depleted allogeneic stem
cell transplantation,” Haematologica, vol. 91, no. 10, pp. 1372–
1376, 2006.
[22] W. J. F. M. van der Velden, N. M. A. Blijlevens, F. M.
H. M. Maas et al., “NOD2 polymorphisms predict severe
acute graft-versus-host and treatment-related mortality in T-
cell-depleted haematopoietic stem cell transplantation,” Bone
Marrow Transplantation, vol. 44, no. 4, pp. 243–248, 2009.
[23] J. A. Hansen, E. W. Petersdorf, M.-T. Lin et al., “Genetics of
allogeneic hematopoietic cell transplantation. Role of HLA
matching, functional variation in immune response genes,”
Immunologic Research, vol. 41, no. 1, pp. 56–78, 2008.
[24] D. Sairaﬁ, M. Uzunel, M. Remberger, O. Ringd´ en, and J.
Mattsson, “No impact of NOD2/CARD15 on outcome after
SCT,” Bone Marrow Transplantation, vol. 41, no. 11, pp. 961–
964, 2008.
[25] Y. Nguyen, A. Al-Lehibi, E. Gorbe et al., “Insuﬃcient evidence
for association of NOD2/CARD15 or other inﬂammatory
bowel disease-associated markers on GVHD incidence or
other adverse outcomes in T-replete, unrelated donor trans-
plantation,” Blood, vol. 115, no. 17, pp. 3625–3631, 2010.
[26] E. Holler, G. Rogler, J. Brenmoehl et al., “The role of genetic
variants of NOD2/CARD15, a receptor of the innate immune
system, in GvHD and complications following related and
unrelated donor haematopoietic stem cell transplantation,”
International Journal of Immunogenetics,v o l .3 5 ,n o .4 - 5 ,p p .
381–384, 2008.
[27] N. P. Mayor, B. E. Shaw, D. A. Hughes et al., “Single nucleotide
polymorphisms in the NOD2/CARD15 gene are associated
with an increased risk of relapse and death for patients with
acute leukemia after hematopoietic stem-cell transplantation
with unrelated donors,” Journal of Clinical Oncology, vol. 25,
no. 27, pp. 4262–4269, 2007.
[28] N.P.Mayor,B.E.Shaw,J.A.Madrigal,andS.G.E.Marsh,“No
impact of NOD2/CARD15 on outcome after SCT: a reply,”
Bone Marrow Transplantation, vol. 42, no. 12, pp. 837–838,
2008.
[29] E. Holler, J. Hahn, R. Andreesen et al., “NOD2/CARD15
polymorphisms in allogeneic stem-cell transplantation from
unrelated donors: T depletion matters,” Journal of Clinical
Oncology, vol. 26, no. 2, pp. 338–339, 2008.
[30] G. C. Hildebrandt, M. Granell, A. Urbano-Ispizua et al.,
“Recipient NOD2/CARD15 variants: a novel independent risk
factor for the development of bronchiolitis obliterans after
allogeneic stem cell transplantation,” Biology of Blood and
Marrow Transplantation, vol. 14, no. 1, pp. 67–74, 2008.
[31] J.Wehkamp,M.Koslowski,G.Wang,andE.F.Stange,“Barrier
dysfunction due to distinct defensin deﬁciencies in small
intestinal and colonic Crohn’s disease,” Mucosal Immunology,
vol. 1, no. 1, pp. S67–S74, 2008.
[32] O. Penack, O. M. Smith, A. Cunningham-Bussel et al., “NOD2
regulates hematopoietic cell function during graft-versus-host
disease,” JournalofExperimentalMedicine,vol.206, no. 10,pp.
2101–2110, 2009.
[33] K. Landfried, F. Bataille, G. Rogler et al., “Recipient
NOD2/CARD15 status aﬀects cellular inﬁltrates in human
intestinal graft-versus-host disease,” Clinical and Experimental
Immunology, vol. 159, no. 1, pp. 87–92, 2010.
[34] D. W. van Bekkum and S. Knaan, “Role of bacterial microﬂora
in development of intestinal lesions from graft versus host
reaction,” Journal of the National Cancer Institute, vol. 58, no.
3, pp. 787–790, 1977.
[35] I. A. Lampert, R. H. Moore, R. Huby, and J. Cohen,
“Observations on the role of endotoxin in graft-versus-host
disease,” Progress in Clinical and Biological Research, vol. 272,
pp. 351–359, 1988.
[36] D. Veenendaal, F. de Boer, and D. van der Waaij, “Eﬀect of
selective decontamination of the digestive tract of donor and
recipient on the occurrence of murine delayed-type graft-
versus-host disease,” Medical Microbiology and Immunology,
vol. 177, no. 3, pp. 133–144, 1988.
[37] P. J. Heidt and J. M. Vossen, “Experimental and clinical
gnotobiotics: inﬂuence of the microﬂora on graft-versus-host
disease after allogeneic bone marrow transplantation,” Journal
of Medicine, vol. 23, no. 3-4, pp. 161–174, 1992.
[38] D. W. Beelen, E. Haralambie, H. Brandt et al., “Evidence that
sustained growth suppression of intestinal anaerobic bacteria
reduces the risk of acute graft-versus-host disease after sibling6 International Journal of Inﬂammation
marrow transplantation,” Blood, vol. 80, no. 10, pp. 2668–
2676, 1992.
[39] D. W. Beelen, A. Elmaagacli, K.-D. M¨ uller, H. Hirche, and U.
W. Schaefer, “Inﬂuence of intestinal bacterial decontamina-
tion using metronidazole and ciproﬂoxacin or ciproﬂoxacin
alone on the development of acute graft- versus-host disease
after marrow transplantation in patients with hematologic
malignancies: ﬁnal results and long-term follow-up of an
open-label prospective randomized trial,” Blood, vol. 93, no.
10, pp. 3267–3275, 1999.
[40] J. Cohen, R. H. Moore, S. Al Hashimi, L. Jones, J. F. Apperley,
and V. R. Aber, “Antibody titres to a rough-mutant strain
of Escherichia coli in patients undergoing allogeneic bone-
marrowtransplantation.Evidenceofaprotectiveeﬀectagainst
graft-versus-host disease,” Lancet, vol. 1, no. 8523, pp. 8–11,
1987.
[41] R. H. Moore, I. A. Lampert, Y. Chia, V. R. Aber, and J.
Cohen, “Eﬀect of immunization with Escherichia coli J5 on
graft-versus-host disease induced by minor histocompatibility
antigens in mice,” Transplantation, vol. 44, no. 2, pp. 249–253,
1987.
[42] H.-G. Klingemann, M. J. Barnett, D. E. Reece, J. D. Shepherd,
and G. L. Phillips, “Use of an immunoglobulin preparation
enriched for IgM (Pentaglobin) for the treatment of acute
graft-versus-host disease,” Bone Marrow Transplantation, vol.
6, no. 3, pp. 199–202, 1990.
[43] A. Gerbitz, M. Schultz, A. Wilke et al., “Probiotic eﬀects on
experimental graft-versus-host disease: let them eat yogurt,”
Blood, vol. 103, no. 11, pp. 4365–4367, 2004.
[44] R. Chakraverty, D. Cˆ ot´ e, J. Buchli et al., “An inﬂammatory
checkpoint regulates recruitment of graft-versus-host reactive
T cells to peripheral tissues,” Journal of ExperimentalMedicine,
vol. 203, no. 8, pp. 2021–2031, 2006.
[45] P. A. Taylor, M. J. Ehrhardt, C. J. Lees et al., “TLR agonists
regulate alloresponses and uncover a critical role for donor
APCs in allogeneic bone marrow rejection,” Blood, vol. 112,
no. 8, pp. 3508–3516, 2008.
[46] C. Calcaterra, L. Sfondrini, A. Rossini et al., “Critical role of
TLR9 in acute graft-versus-host disease,” Journal of Immunol-
ogy, vol. 181, no. 9, pp. 6132–6139, 2008.
[47] M. M. Horowitz, R. P. Gale, P. M. Sondel et al., “Graft-versus-
leukemia reactions after bone marrow transplantation,” Blood,
vol. 75, no. 3, pp. 555–562, 1990.
[48] L. K. Jasperson, C. Bucher, A. Panoskaltsis-Mortari et al.,
“Indoleamine 2,3-dioxygenase is a critical regulator of acute
graft-versus-host disease lethality,” Blood, vol. 111, no. 6, pp.
3257–3265, 2008.